Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Daybue — Revenue

Other product segments

Nuplazid
$166.92M+4.5%

Similar metrics at other companies

Mobileye Global Inc. logo
MBLYDE — Revenue
$77M+4.1%
PTC Therapeutics logo
PTCTUpstaza And Kebilidi — Revenue
$9.59M+10.8%
Bel Fuse logo
BELFBDE — Revenue
$3.68M-3.6%
Lantheus Holdings logo
LNTHDefinity — Revenue
$84.63M+6.8%
Novanta logo
NOVTDE — Revenue
$36.29M+27.5%
Lantheus Holdings logo
LNTHProduct — Revenue
$369.85M+0.8%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.7B+37.0%
Enterprise value$3.47B+36.6%
P/E9.9×-2.0×
P/S3.4×+0.7×

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's daybue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's daybue — revenue?
Acadia Pharmaceuticals (ACAD) reported daybue — revenue of $101.14M in Q1 2026.
How has Acadia Pharmaceuticals's daybue — revenue changed year-over-year?
Acadia Pharmaceuticals's daybue — revenue increased by 19.6% year-over-year, from $84.6M to $101.14M.
What does daybue — revenue mean?
This metric represents the total net sales generated from the commercialization of the Daybue product, excluding any taxes collected on behalf of government authorities. It serves as a primary indicator of the product's market adoption, commercial traction, and contribution to the company's overall top-line growth within the central nervous system disorder therapeutic market. Tracking this revenue stream allows investors to evaluate the successful execution of the product launch and its ongoing performance against competitive alternatives.